RVL Pharmaceuticals PLC expected to post a loss of 27  cents a share - Earnings Preview

RVL Pharmaceuticals

28/03/2022 21:04

* RVL Pharmaceuticals PLC  RVLP.OQ   RVLP.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 30. 
    * The Bridgewater New Jersey-based  company is expected to
report 
a 91.0% decrease in revenue to $3.102 million from $34.53
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for RVL Pharmaceuticals
PLC
is for a loss of 27 cents per share. For the same quarter last
year, the company reported a loss of 88 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for RVL
Pharmaceuticals PLC is $5.5​, above​ its last closing price
of $1.85. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.31       -0.31      -0.28     Beat    11.1
 Jun. 30 2021  -0.14       -0.14      -0.28     Missed  -100
 Mar. 31 2021  -0.23       -0.23      -0.15     Beat    36.2​
 Dec. 31 2020  -0.28       -0.24      -0.88     Missed  -271.8
 ​​Sep.        -0.20       -0.20      -0.14     Beat    30
 30 2020                                                
 Jun. 30 2020  -0.12       -0.12      -0.22     Missed  -76​
 Mar. 31 2020  -0.15       -0.14      -0.05     Beat    65.1
 Dec. 31 2019  -0.09       -0.06      -0.51     Missed  -696.9
 This summary was machine generated March 28 at 20:04 GMT.  All
figures in US dollars  unless otherwise stated